Document Detail

Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
MedLine Citation:
PMID:  22785204     Owner:  NLM     Status:  MEDLINE    
The epidermal growth factor receptor (EGFR) is widely expressed in head and neck squamous cell carcinomas (HNSCC) and can activate many growth and survival pathways within tumor cells. Despite ubiquitous EGFR expression, therapies targeting the receptor are only modestly effective in the treatment of HNSCC. A consistent mechanism of resistance to EGFR targeting agents has not yet been identified in HNSCC likely due, in part, to the paucity of preclinical models. We assessed the in vitro and in vivo responses of a panel of 10 genotypically validated HNSCC cell lines to the EGFR inhibitors erlotinib and cetuximab to determine their validity as models of resistance to these agents. We defined a narrow range of response to erlotinib in HNSCC cells in vitro and found a positive correlation between EGFR protein expression and erlotinib response. We observed cross-sensitivity in one HNSCC cell line, 686LN, between erlotinib and cetuximab in vivo. We attempted to generate models of cetuximab resistance in HNSCC cell line-derived xenografts and heterotopic tumorgrafts generated directly from primary patient tumors. While all 10 HNSCC cell line xenografts tested were sensitive to cetuximab in vivo, heterotopic patient tumorgrafts varied in response to cetuximab indicating that these models may be more representative of clinical responses. These studies demonstrate the limitations of using HNSCC cell lines to reflect the heterogeneous clinical responses to erlotinib and cetuximab, and suggest that different approaches including heterotopic tumorgrafts may prove more valuable to elucidate mechanisms of clinical resistance to EGFR inhibitors in HNSCC.
Kelly M Quesnelle; Sarah E Wheeler; Mary K Ratay; Jennifer R Grandis
Related Documents :
3072134 - A comparison of high frequency switching in the yeast candida albicans and the slime mo...
25176024 - In vitro modeling of her2-targeting therapy in disseminated prostate cancer.
2640294 - Investigations on contractile properties of retinal pigment epithelial cells.
1586944 - Culmination in dictyostelium is regulated by the camp-dependent protein kinase.
16973744 - The herpesvirus glycoproteins b and h.l are sequentially recruited to the receptor-boun...
24030034 - Somatic cell transformation into stem cell-like cells induced by different microenviron...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2012-08-01
Journal Detail:
Title:  Cancer biology & therapy     Volume:  13     ISSN:  1555-8576     ISO Abbreviation:  Cancer Biol. Ther.     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-08-03     Completed Date:  2012-12-14     Revised Date:  2013-08-12    
Medline Journal Info:
Nlm Unique ID:  101137842     Medline TA:  Cancer Biol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  935-45     Citation Subset:  IM    
Department of Pharmacology & Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / administration & dosage,  pharmacology*
Antineoplastic Agents / administration & dosage,  pharmacology*
Carcinoma, Squamous Cell / drug therapy*,  metabolism
Cell Line, Tumor
Drug Resistance, Neoplasm / drug effects
Head and Neck Neoplasms / drug therapy*,  metabolism
Inhibitory Concentration 50
Mice, Nude
Protein Kinase Inhibitors / administration & dosage,  pharmacology*
Quinazolines / administration & dosage,  pharmacology*
Receptor, Epidermal Growth Factor / antagonists & inhibitors*,  metabolism
Tumor Burden / drug effects
Xenograft Model Antitumor Assays
Grant Support
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antineoplastic Agents; 0/Protein Kinase Inhibitors; 0/Quinazolines; EC, Epidermal Growth Factor; J4T82NDH7E/erlotinib; PQX0D8J21J/cetuximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Biomarkers-A Pot of gold or a can of worms?: Meeting report from the 2nd world congress on biomarker...
Next Document:  Inauhzin and Nutlin3 synergistically activate p53 and suppress tumor growth.